Equities research analysts expect that Reata Pharmaceuticals Inc (NASDAQ:RETA) will report ($0.82) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Reata Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.99). Reata Pharmaceuticals reported earnings of ($0.50) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 64%. The firm is expected to announce its next earnings report on Monday, November 12th.
On average, analysts expect that Reata Pharmaceuticals will report full year earnings of ($2.59) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.26). For the next year, analysts anticipate that the firm will post earnings of ($3.49) per share, with EPS estimates ranging from ($4.16) to ($3.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.34). The company had revenue of $7.57 million for the quarter, compared to analyst estimates of $9.11 million.
Shares of NASDAQ RETA traded down $1.08 during trading hours on Friday, hitting $61.26. 873 shares of the stock were exchanged, compared to its average volume of 292,844. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of -0.47. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -31.26 and a beta of 2.79. Reata Pharmaceuticals has a 1-year low of $19.31 and a 1-year high of $99.50.
In other Reata Pharmaceuticals news, insider Elaine Castellanos sold 7,336 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The shares were sold at an average price of $50.81, for a total value of $372,742.16. Following the sale, the insider now owns 140 shares in the company, valued at $7,113.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James Edward Bass bought 888 shares of the business’s stock in a transaction on Wednesday, July 25th. The stock was bought at an average price of $78.34 per share, for a total transaction of $69,565.92. Following the transaction, the director now directly owns 51,543 shares of the company’s stock, valued at $4,037,878.62. The disclosure for this purchase can be found here. Company insiders own 31.69% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp raised its stake in shares of Reata Pharmaceuticals by 1.4% during the first quarter. Northern Trust Corp now owns 129,984 shares of the company’s stock valued at $2,666,000 after acquiring an additional 1,735 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Reata Pharmaceuticals by 53.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock valued at $191,000 after acquiring an additional 1,897 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in shares of Reata Pharmaceuticals by 72.7% during the second quarter. MetLife Investment Advisors LLC now owns 7,732 shares of the company’s stock valued at $270,000 after acquiring an additional 3,255 shares during the last quarter. Woodstock Corp raised its stake in shares of Reata Pharmaceuticals by 20.1% during the second quarter. Woodstock Corp now owns 23,730 shares of the company’s stock valued at $830,000 after acquiring an additional 3,978 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Reata Pharmaceuticals during the second quarter valued at $154,000. 46.63% of the stock is owned by hedge funds and other institutional investors.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Further Reading: Asset Allocation Models, Which is Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.